Prestige Consumer Healthcare Inc.
$58.68
▼
-9.02%
2026-04-21 08:45:02
www.prestigebrands.com
NYQ: PBH
Explore Prestige Consumer Healthcare Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.78 B
Current Price
$58.68
52W High / Low
$89.37 / $51.24
Stock P/E
14.89
Book Value
$38.66
Dividend Yield
—
ROCE
10.6%
ROE
10.31%
Face Value
—
EPS
$3.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
600
Beta
0.47
Debt / Equity
58.99
Current Ratio
3.11
Quick Ratio
2.82
Forward P/E
11.76
Price / Sales
2.46
Enterprise Value
$3.69 B
EV / EBITDA
10.12
EV / Revenue
3.35
Rating
None
Target Price
$78.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
| 2. | Gelteq Limited | $0.7 | — | $7.5 M | — | -31.25% | -42.99% | $4.11 / $0.64 | $1.09 |
| 3. | Alkermes plc | $34.23 | 23.69 | $5.73 B | — | 13.07% | 14.72% | $36.48 / $25.16 | $10.99 |
| 4. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
| 5. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 6. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
| 7. | Sonoma Pharmaceuticals, Inc. | $2.65 | — | $4.59 M | — | -38.66% | -81.18% | $6.92 / $2 | $1.98 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 283.44 M | 274.11 M | 249.53 M | 296.52 M | 290.32 M | — |
| Operating Profit | 82.49 M | 79.67 M | 71.76 M | 100.89 M | 91.96 M | — |
| Net Profit | 46.7 M | 42.21 M | 47.47 M | 50.13 M | 61.03 M | — |
| EPS in Rs | 0.99 | 0.89 | 1 | 1.06 | 1.29 | 1.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.14 B | 1.13 B | 1.13 B | 1.09 B |
| Operating Profit | 349.24 M | 342.43 M | 347.8 M | 330.98 M |
| Net Profit | 214.6 M | 209.34 M | -82.31 M | 205.38 M |
| EPS in Rs | 4.54 | 4.42 | -1.74 | 4.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.4 B | 3.32 B | 3.35 B | 3.67 B |
| Total Liabilities | 1.57 B | 1.66 B | 1.91 B | 2.09 B |
| Equity | 1.83 B | 1.66 B | 1.45 B | 1.58 B |
| Current Assets | 448.33 M | 375.04 M | 391.74 M | 293.27 M |
| Current Liabilities | 106.62 M | 117.05 M | 160.72 M | 143.42 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 251.51 M | 248.93 M | 229.72 M | 259.92 M |
| Investing CF | -17.45 M | -20.11 M | -11.58 M | -256.51 M |
| Financing CF | -182.07 M | -241.01 M | -185.85 M | -7.57 M |
| Free CF | 243.29 M | 239.38 M | 221.93 M | 250.28 M |
| Capex | -8.22 M | -9.55 M | -7.78 M | -9.64 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 1.1% | -0.21% | 3.76% | — |
| Earnings Growth % | 2.52% | 354.34% | -140.07% | — |
| Profit Margin % | 18.86% | 18.6% | -7.3% | 18.9% |
| Operating Margin % | 30.7% | 30.43% | 30.84% | 30.45% |
| Gross Margin % | 55.76% | 55.49% | 55.45% | 57.11% |
| EBITDA Margin % | 31.82% | 33.22% | 0.7% | 33.02% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.